Xenon's Azetukalner Achieves Breakthrough Seizure Control in Phase 3 X-TOLE2 Study—Nearly 40% Achieve Year-Long Freedom After Four Years
Double-Digit Efficacy: Over 50% Seizure Reduction Observed in X-TOLE2 Trial
Xenon Pharmaceuticals’ latest Phase 3 X-TOLE2 trial data, presented at the 2026 AAN Annual Meeting, reveal that azetukalner could redefine the treatment of focal onset seizures (FOS). In a patient group with highly treatment-resistant epilepsy, those treated with 25 mg azetukalner achieved a median 53.2% reduction in monthly seizure frequency over 12 weeks, compared to a 10.4% reduction with placebo. The 15 mg group also saw a substantial 34.5% decrease. Notably, efficacy improvements appeared as early as week one and remained robust throughout the double-blind period.
| Group | Median Percent Change (12 weeks) | =50% Responder Rate | 100% Seizure-Free Rate (End of DBP) |
|---|---|---|---|
| AZK 25 mg | -53.2% | Higher vs Placebo (Stat. Sig.) | 6.5% |
| AZK 15 mg | -34.5% | Higher vs Placebo (Stat. Sig.) | — |
| Placebo | -10.4% | — | 0.8% |
Responder rates improved over time—by the final four weeks, 13.7% of the 25 mg group were seizure-free, compared to just 4.0% for placebo.
Long-Term Data: Nearly 40% Achieve Year-Long Seizure Freedom, 1-in-4 for Two Years
In interim findings from the X-TOLE open-label extension (OLE), participants treated with azetukalner for 48 months experienced a median 90.9% reduction in monthly seizures. Of these, 38.2% enjoyed at least 12 consecutive months without seizures—the clinical benchmark for seizure freedom—and 25.2% maintained this for two years, highlighting profound sustained efficacy.
| Consecutive Seizure-Free Duration | Percentage of Participants |
|---|---|
| =12 months | 38.2% |
| =24 months | 25.2% |
| =36 months | 19.8% |
| =48 months | 10.7% |
Those with less refractory disease (fewer concomitant anti-seizure medications) saw even greater benefit—with a 100% seizure reduction at 48 months for those on one or two ASMs at baseline.
Safety and Tolerability Remain Consistent Over Years of Use
Azetukalner’s safety profile held steady between short and long-term studies. Reported side effects—dizziness, headache, somnolence, and fatigue—were generally mild and infrequently led to discontinuation. There were no observed increases in serious adverse events or life-altering side effects, including weight gain or cardiac issues, even after more than 775 patient-years of exposure.
No Titration Needed: Patients and Physicians Highlight Quality-of-Life Advantages
Unlike many anti-seizure medications that require gradual dose escalation (titration), azetukalner offers once-daily dosing with no need for titration or adjustment due to drug interactions. Real-world surveys show this can significantly lower treatment stress: 90% of patients said starting an ASM without titration increased their confidence; 77% reported reduced anxiety; and 84% noted improved medication adherence. Physicians echoed these benefits, pointing to simplified care—especially valuable for patients already navigating complex medication regimens.
Takeaway: Azetukalner May Redefine Seizure Management
These latest results suggest azetukalner could become a first-in-class, preferred option for people battling focal onset seizures—combining rapid and sustained seizure control with a patient-friendly dosing schedule. With a New Drug Application planned for late 2026, both patients and clinicians should monitor upcoming regulatory developments and further clinical updates as this therapy advances toward broader use.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI